可溶性syndecan-1分子水平与人多发性骨髓瘤预后的相关性研究  

Relative study of soluble syndecan-1 and prognosis of patients with multiple myeloma

作　　者：李新燕[1] 张学光[1] 陆肇阳[1] B Klein 

机构地区：[1]苏州大学生命医学生物技术研究所,215006 [2]法国蒙彼利埃总医院

出　　处：《中华血液学杂志》2001年第6期303-305,共3页Chinese Journal of Hematology

基　　金：国家自然科学青年基金资助项目 !(3 970 0 13 0 ) ;国家自然科学基金资助项目 !(3 0 0 70 841)

摘　　要：目的　分析可溶性syndecan 1分子与人多发性骨髓瘤 (MM)预后的相关性。方法　用ELISA酶联免疫检测法定量分析MM和浆细胞白血病患者血浆syndecan 1水平。结果　①初诊MM患者血浆syndecan 1含量中位数为 111mg/L ,是正常人 (6 3mg/L)的 1.76倍 (P <0 .0 0 5 ) ,而浆细胞白血病患者血浆syndecan 1水平中位数为 16 45mg/L ,较正常人高 2 6倍 (P <0 .0 0 1) ;②可溶性syndecan 1分子水平高低与MM患者的预后呈负相关 ,即可溶性syndecan 1分子水平大于 16 6mg/L ,其平均生存期为 18个月 ,而小于 16 6mg/L的MM患者 ,其平均生存期为 48个月 ,两者差异有显著性 (P =0 .0 0 42 )。③可溶性syndecan 1分子升高水平与 β2 微球蛋白、浆细胞水平相一致。结论　可溶性syndecan 1分子水平为影响MM预后的因素之一 。Objective To investigate the role of soluble syndecan 1 in the pathogenesis of human multiple myeloma (MM). Methods Serum level of soluble syndecan 1 of patients with MM and plasma cell leukemia was determined by ELISA. Results ①The median serum soluble syndecan 1 concentrations of MM patients and controls were 111?ng/ml (41～6?300?mg/L) and 63?mg/L (10～163?mg/L), respectively(P<0.005). ② For 47 myeloma patients, increased serum syndecan 1 concentrations at diagnosis were associated with a poor prognosis. Patients with serum syndecan 1 levels below or above 166?mg/L had significantly different survival times (median > 48 months or < 18 months, respectively, P<0.0001). ③Serum soluble syndecan 1 levels were correlated with beta 2 microglobulin concentrations and the percentage of plasma cell. Conclusion Serum levels of circulating soluble syndecan 1 correlated with tumor mass and may exert pleiotropic effects on myeloma cell behavior.

关 键 词：多发性骨髓瘤 可溶性syndecan-1分子 预后 相关性研究 

分 类 号：R733.3[医药卫生—肿瘤]